Zacks Research Analysts Lift Earnings Estimates for Omnicell

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research upped their Q1 2025 earnings estimates for Omnicell in a report released on Thursday, November 14th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.15 for the quarter, up from their previous estimate of $0.14. The consensus estimate for Omnicell’s current full-year earnings is $0.74 per share. Zacks Research also issued estimates for Omnicell’s Q2 2025 earnings at $0.18 EPS.

Several other analysts also recently weighed in on the company. Barclays raised their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Bank of America restated a “neutral” rating and set a $57.00 price objective (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Wells Fargo & Company increased their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Craig Hallum lifted their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, JPMorgan Chase & Co. increased their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $50.83.

Omnicell Stock Performance

Shares of NASDAQ:OMCL opened at $46.05 on Monday. The business’s 50-day simple moving average is $44.20 and its 200 day simple moving average is $36.96. The company has a market cap of $2.13 billion, a P/E ratio of -118.07, a PEG ratio of 43.97 and a beta of 0.81. Omnicell has a one year low of $25.12 and a one year high of $55.74.

Institutional Investors Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently modified their holdings of OMCL. Vanguard Group Inc. raised its holdings in Omnicell by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after purchasing an additional 80,312 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after buying an additional 508,789 shares in the last quarter. Champlain Investment Partners LLC raised its stake in shares of Omnicell by 16.0% in the 1st quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after buying an additional 241,235 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Omnicell by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock valued at $31,955,000 after buying an additional 3,570 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after buying an additional 1,138,921 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.